Amgen drug shows blockbuster promise
Putting test results behind the talk at its recent product pipeline review, Thousand Oaks-based Amgen on May 17 released promising results for the Xgeva variant of its potential blockbuster bone drug denosumab.
Read More →Beyond biologics: Amgen bets new drugs will pay dividend
Amgen executives believe the biotech giant will grow substantially in the next decade, pursuing drugs that treat major melanoma and bone loss.
Read More →Amgen gets sought-after FDA approval
The Food and Drug Administration has approved the use of Amgen’s bone drug denosumab in patients with certain types of cancer, Amgen announced Nov. 18.
Read More →Amgen reports earnings drop
Thousand Oaks-based Amgen said Oct. 25 that third-quarter earnings fell 14 percent to $1.3 billion as revenue flatlined. Amgen is the world’s biggest biotech company and the largest private employer in the Tri-Counties. It reported adjusted earnings per share of $1.36, a decrease of 9 percent compared to the same quarter last year. Total revenue Read More →
Read More →FDA OKs Aranesp for pre-dialysis patients
Amgen’s anemia treatment Aranesp is safe for kidney patients whose disease doesn’t require dialysis, a federal panel announced Oct. 18 in response to a study that found the drug could increase stroke risk in those patients. Outside advisers to the U.S. Food and Drug Administration said the treatment shouldn’t be withdrawn or limited to a Read More →
Read More →2011 Amgen tour to hit Paso, Solvang, T.O.
Paso Robles, Solvang and Thousand Oaks will all play host to parts of the 2011 Amgen Tour of California cycling race, Amgen and the race’s other organizers announced Oct. 7. The eight-day, 800-mile race starts May 15 in South Lake Tahoe and winds its way down the state to finish May 22 in Amgen’s home Read More →
Read More →
Sponsored content:
2015-2016 Giving Guide
